secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2023-06-06T23:59:59+00:00
Accession:  0001193125-23-161596
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences reports positive Phase 3 PEAK lead-in data for bezuclastinib in GIST
--------------------------------------------------------------------------------

- 39 patients treated; 55% disease control rate across efficacy-evaluable patients in Part 1.
- In 2nd-line Part 1a: 100% disease control rate and 17% overall response rate.
- Safety profile well-tolerated; 2 discontinuations due to AEs; low Grade ≥3 events.
- Part 2 enrollment ongoing (target ~388 2nd-line GIST patients); SUMMIT/APEX data expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312523161596/0001193125-23-161596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312523161596/d425875d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-161596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer